#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Michel Chrétienne Email
Head Pharmaceutical Compliance . Legacy Healthcare’s
Epalinges,
LocationM***********@legacyhealthcare.ch
Primary EmailHow to contact Michel Chrétienne
Join and see Michel's contact info for free!Current Roles
Employees:
17Revenue:
$2.6MAbout
Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile population, e.g. children, cancer patients and the elderly, who may be already on multiple medications. Our first drug, Coacillium, is currently in Phase II/III testing for the treatment of Alopecia Areata, a debilitating scalp condition with intense medical and psychological impact on all patients, especially in children, and their families. Coacillium's safety profile is without equal. For this reason health authorities have taken the unusual step of authorizing testing in children (starting at age 2) before adult testing. We expect Coacillium to be approved by 2023, as the first drug for Pediatric Alopecia Areata.Legacy Healthcare’s Address
Route de la Corniche 3BEpalinges, null